VVT Med Advances Portugal Market Entry as Dermworks Begins ScleroSafe® Market Evaluation and Announces Corporate Updates

Initial Order Supplied to Dermworks; Market Research and Initial Physician Demonstrations to Begin Following Earlier Independent Physician Experience in Portugal

VANCOUVER, BC, Sept. 1, 2026 /CNW/ -- VVT Med Inc. (TSXV: VVTM) ("VVT Med" or the "Company"), a developer of minimally invasive, non-thermal, non-tumescent ("NT-NT") solutions for venous disease, today announced progress in its entry into the Portuguese market under its Trial Distribution and Evaluation Agreement (the "Agreement") with Dermworks, a Portuguese pharmaceutical and medical device distributor.

Under the Agreement, Dermworks has been appointed as VVT Med's exclusive trial distributor for ScleroSafe^® in Portugal, with conditional exclusivity tied to defined training and purchase obligations. The Agreement includes an initial purchase order and establishes an evaluation period and a defined pathway toward a potential five-year exclusive distribution partnership, subject to the parties reaching mutually agreed terms prior to the conclusion of the evaluation period.

Since execution of the Agreement, the initial order of ScleroSafe^® Full Sets has been supplied to Dermworks. Dermworks is now preparing to initiate market research and initial physician demonstrations to evaluate the commercial opportunity and introduce the technology to selected physicians in Portugal.

The Dermworks evaluation follows earlier independent physician experience with ScleroSafe^® in Portugal under the direction of Dr. José Pereira Albino, together with his assistant, Dr. João Vieira. Drs. Albino and Vieira gained hands-on experience with the technology prior to Dermworks' involvement, with Dr. Albino being the first physician to introduce and use ScleroSafe^® in Portugal. Based on Dr. Albino's initial experience using ScleroSafe^® in a limited number of procedures involving both great saphenous vein (GSV) and small saphenous vein (SSV) treatments, immediate vein closure was observed at the time of treatment. These observations reflect the physician's individual experience and are not intended to be representative of broader clinical outcomes.

Dr. Albino reported that, in his experience, the system's controlled delivery mechanism and catheter design assisted with procedural navigation in tortuous venous anatomy. This earlier physician experience was independent of Dermworks' current market evaluation activities and provided VVT Med with initial clinical experience with ScleroSafe^® in the Portuguese market.

"Portugal represents another important step in the expansion of our European commercial footprint," said Erez Tetro, Chief Executive Officer of VVT Med. "We are pleased to have progressed from execution of the agreement to supplying Dermworks with its initial order and supporting the beginning of its market evaluation activities. Importantly, this process follows earlier independent physician experience with ScleroSafe^® in Portugal by Dr. José Pereira Albino and Dr. João Vieira, including both GSV and SSV procedures, providing a useful foundation as Dermworks begins introducing the technology to additional physicians and evaluating the broader commercial opportunity."

The Portuguese market entry builds on VVT Med's expanding European activities. The Company has previously announced commercialization activities in Italy and has recorded more than 150 ScleroSafe^® procedures in North Macedonia. Portugal joins VVT Med's growing commercial network spanning the United States, India, South Korea, and Europe, as the Company continues to expand access to its NT-NT technology.

Financing Update
The Company wishes to provide an update on its non-brokered private placement offering of up to $3,000,000 in gross proceeds (the "Offering"). The Company completed the first tranche of the Offering on April 22, 2026 and currently intends to complete a second tranche in early September 2026 and a third and final tranche on the same terms by the end of September 2026.

The Offering consists of units (each, a "Unit") at a price of $0.25 per Unit, with each Unit comprised of one common share of the Company and one-half of one common share purchase warrant (each whole warrant, a "Warrant"). Each Warrant is exercisable to acquire one common share at an exercise price of $0.375 for a period of 24 months from the date of issuance.

The net proceeds of the Offering are expected to be used to support expanded U.S. and global commercialization efforts, product manufacturing, working capital and general corporate purposes. Securities issued pursuant to any future tranche of the Offering will be subject to a four-month hold period from the date of issuance in accordance with applicable securities laws and the policies of the TSX Venture Exchange.

The completion of any additional tranche of the Offering remains subject to receipt of all necessary regulatory approvals, including acceptance by the TSX Venture Exchange. There can be no assurance that any additional tranche of the Offering will be completed on the terms described, or at all.

Marketing and Investor Awareness Engagement

The Company also announces that it has entered into an advertising services agreement with CEO.CA Technologies Ltd. ("CEO.CA") dated August 12, 2026, pursuant to which CEO.CA will provide advertising, marketing and investor awareness services for a 12-month term, commencing on September 15, 2026. The engagement includes digital advertising, featured news distribution, video interviews, sponsorship opportunities and other investor awareness initiatives through the CEO.CA platform. In consideration for the services, the Company will pay CEO.CA an aggregate fee of C$110,000 plus applicable taxes. The agreement is intended to increase market awareness of the Company and its business activities. To the knowledge of the Company, CEO.CA and its principals are arm's length to the Company and do not hold any securities of the Company.

Investor Relations Update

The Company further announces that its investor relations agreement with Investor Cubed Inc. ("i3") was terminated effective August 21, 2026. The Company thanks i3 for its services and wishes it success in its future endeavours.

Debt Settlement Update

The Company also wishes to correct certain information contained in its August 21, 2026 news release entitled"VVT Med Announces Debt Settlement and Equity Incentive Grants to Strengthen Capital Structure." The news release incorrectly stated that 125,000 common shares would be issued at a deemed price of $0.56 per share as part of the proposed debt settlement. The Company clarifies that this portion of the debt settlement is proposed to be completed through the issuance of 280,000 common shares at a deemed price of $0.25 per share. All other terms of the proposed debt settlement remain unchanged and continue to be subject to TSX Venture Exchange approval.

About VVT Med Inc. (VVTM)

VVT Medical develops, manufactures, and distributes minimally invasive, non-thermal, non-tumescent (NT-NT) solutions for the treatment of vein diseases, starting with varicose veins. VVT's FDA-cleared and CE-marked catheter-based technologies include ScleroSafe^® and V-Block™. For more information, visit www.vvtmed.com.

About Dermworks

Dermworks is a Portuguese pharmaceutical and medical device distributor specializing in the promotion and commercialization of medical devices, cosmetics, and food supplements. Headquartered near Matosinhos, Dermworks operates as a wholesale supplier to pharmacies and clinics across Portugal. For more information, visit www.dermworks.pt.

Cautionary Note Regarding Forward-Looking Statements

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws (collectively, "forward-looking statements"). Forward-looking statements in this news release include, without limitation, statements regarding: Dermworks' planned market research, physician demonstrations and evaluation activities in Portugal; the potential commercial opportunity for ScleroSafe^® in Portugal; the potential adoption of ScleroSafe^® by physicians and clinics; the anticipated benefits and outcomes of the Agreement with Dermworks; the potential transition from the evaluation period to a long-term exclusive distribution arrangement; the Company's plans to expand its commercial presence in Portugal, Europe and other international markets; the services to be provided by CEO.CA and the anticipated benefits of the Company's marketing and investor awareness initiatives; the intended use of proceeds of the Offering; and the anticipated timing and completion of the second and third tranches of the Offering, including obtaining all required regulatory approvals.

Forward-looking statements are based on a number of assumptions believed by management to be reasonable at the time such statements are made, including assumptions regarding market conditions, regulatory approvals, physician interest and adoption, distributor performance, the successful implementation of commercialization initiatives, the availability of financing on acceptable terms, and the Company's ability to execute its business plan. However, forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others, the risk that Dermworks' evaluation activities may not result in increased adoption, sales or a long-term distribution arrangement, that commercialization efforts may not achieve anticipated results, that market acceptance of ScleroSafe^® may be slower than expected, that regulatory or operational challenges may arise, that the services provided by CEO.CA may not generate the anticipated increase in market awareness, and that additional tranches of the Offering may not be completed on the anticipated timeline or at all.

Readers are cautioned not to place undue reliance on forward-looking statements. Except as required by applicable securities laws, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

This news release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States. The Company's securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE VVT MED INC.

Contact Information: Erez Tetro, Chief Executive Officer, [phone]; Investor Relations, [email protected]